SW · EVT.SW
Evotec SE
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Hamburg 22419
- Website
- evotec.com
Price · as of 2024-12-31
$5.01
Market cap 4.78B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $1.00 | $1.00 | |||
| 2011 | $1.10 | $2.80 | |||
| 2012 | $1.00 | $0.30 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.40 | $0.00 | |||
| 2015 | $1.50 | $5.70 | |||
| 2016 | $1.80 | $6.90 | |||
| 2017 | $1.50 | $9.70 | |||
| 2018 | $4.00 | $27.70 | |||
| 2019 | $2.60 | $6.30 | |||
| 2020 | $3.10 | $0.80 | |||
| 2021 | $12.30 | $37.00 | |||
| 2022 | $0.20 | $0.00 | |||
| 2023 | $2.20 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Evotec SE's (EVT.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.01
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
- CEO
- Mario Polywka DPHIL,
- Employees
- 5.06K
- Beta
- 1.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.01) − 1 = — (DCF, example).